Drug Trial Radar · NCT04775953
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
Last checked: Nov 19, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Apr 22, 2021
Primary completion
Oct 6, 2023
Study completion Dec 1, 2023
Sponsor
- Sponsor type
- NIH
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with complicated bacteremia or right-sided native valve Infective Endocarditis (IE) caused by S. aureus who have cleared their baseline bacteremia. Approximately 200 subjects will be randomized 1:1 to receive either dalbavancin or a standard of care antibiotic regimen that is based upon the identification and antibiotic susceptibility pattern of the baseline organism. Subjects randomized to the dalbavancin treatment group will receive 2 doses of dalbavancin intravenously (IV) 1 week apart (1500 mg on Day 1 and Day 8 after randomization, with renal dose adjustment if appropriate). Subjects randomized to the standard of care antibiotic therapy treatment group will receive an antibiotic regimen considered to be standard of care based on the methicillin susceptibility pattern of the pathogen isolated at baseline for a duration of 4 to 6 weeks and up to 8 weeks for patients with vertebral osteomyelitis/discitis. The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at Day 70 of dalbavancin to that of standard of care antibiotic therapy used to consolidate therapy for the treatment of subjects with complicated S. aureus bacteremia in the intent-to-treat population (ITT).
Conditions
- Staphylococcal Bacteraemia
Interventions
CefazolinDrug
Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
DalbavancinDrug
A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
DaptomycinDrug
Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
NafcillinDrug
Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
OxacillinDrug
Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
VancomycinDrug
Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Desirability of Outcome Ranking (DOOR)Time frame: Day 70
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama Hospital - Infectious Diseases
Birmingham, Alabama
University of California Davis Medical Center - Internal Medicine - Infectious Disease
Sacramento, California
Harbor UCLA Medical Center - Medicine - Infectious Diseases
Torrance, California
Torrance Memorial Medical Center
Torrance, California
University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine
Gainesville, Florida
University of South Florida Health - Internal Medicine
Tampa, Florida
Rush University Medical Center
Chicago, Illinois
Ochsner Health - Ochsner Medical Center - Department of Infectious Diseases
New Orleans, Louisiana
Henry Ford Health System - Henry Ford Hospital
Detroit, Michigan
Corewell Health - Infectious Disease
Royal Oak, Michigan
University of Nebraska Medical Center - Infectious Diseases
Omaha, Nebraska
South Jersey Infectious Disease
Somers Point, New Jersey
New York Presbyterian Hospital - Weill Cornell Medical Center - Infectious Diseases
New York, New York
SUNY Upstate Medical University - Infectious Disease Division
Syracuse, New York
Atrium Health ID Consultants & Infusion Care Specialists
Charlotte, North Carolina
Duke University Hospital - Infectious Diseases
Durham, North Carolina
East Carolina University - Infectious Diseases and Tropical/Travel Medicine Clinic
Greenville, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Oregon Health and Science University - Adult Infectious Diseases Clinic
Portland, Oregon
University of Pittsburgh - Medicine - Infectious Diseases
Pittsburgh, Pennsylvania
Prisma Health - Greenville Health System - Infectious Disease
Greenville, South Carolina
The University of Texas - MD Anderson Cancer Center - Infectious Diseases
Houston, Texas
Carilion Roanoke Memorial Hospital
Roanoke, Virginia
McGill University Health Centre
Montreal, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.